RALTEGRAVIR PACKAGE INSERT PDF

Drug information on Raltegravir for patients and consumers. side effects of raltegravir, read the drug label or package insert or talk to your health care provider. Drug information on Raltegravir Tablet (chewable), tablet (film coated), granule for oral suspension for health care professionals. Drug Label Information. Updated February 7, If you are a See full prescribing information for ISENTRESS. ISENTRESS PATIENT PACKAGE INSERT.

Author: Samule Malagal
Country: Fiji
Language: English (Spanish)
Genre: Medical
Published (Last): 18 January 2011
Pages: 198
PDF File Size: 1.60 Mb
ePub File Size: 15.49 Mb
ISBN: 222-8-59825-699-2
Downloads: 30228
Price: Free* [*Free Regsitration Required]
Uploader: Kazrazragore

Use with caution if benefits outweigh risks. No dose adjustment required Severe Child Pugh C: Isentress, Isentress HD Classes: In animal reproduction studies in rats and rabbits, no evidence of adverse developmental outcomes observed with oral administration during organogenesis at doses that produced exposures up to approximately 4 times maximal recommended human dose MRHD of mg.

All Interactions Sort By: Most commonly, these are “non-preferred” brand drugs. This drug is available at a middle level co-pay.

This restriction requires that specific clinical criteria be met prior to the approval of the prescription. Animal studies show risk and human studies not available or neither animal nor human studies done.

Access Denied

Brand and Other Names: Prior Authorization Drugs that require prior authorization. Your list will be saved and can be edited at any time. Dosing Considerations Combination regimen is based on safety, ralteggravir, pharmacokinetic parameters, and efficacy data through at least wk in a multicenter, open-label, noncomparative study in HIV-1 infected children and adolescents raltegrvir 4 wk raltegraivr 18 yr Do not substitute chewable tablets or oral suspension for film-coated tablets; these are not bioequivalent, and therefore, are not interchangeable Do not switch between film-coated mg and mg tablet if prescribed dose is mg.

Owing to the potential for HIV transmission in HIV-negative infantsdeveloping viral resistance in HIV- positive infantsand adverse reactions in a breastfed infant, instruct mothers not to breastfeed if they are receiving therapy. Risks involved outweigh potential benefits.

Raltegravir (MK-0518, Isentress)

Effect of food Low fat AUC ratio: Rhabdomyolysis Nervous system disorders: To view formulary information first create a list of plans. Share cases and questions with Physicians on Medscape consult. Chewable tablets contain phenylalanine, a component of aspartame Drug interactions overview Coadministration of raltegravir with drugs that inhibit UGT1A1 eg, rifampin may reduce plasma levels of raltegravir see Dosage Modifications Coadministration with other strong inducers eg, carbamazepine, phenobarbital, phenytoin of drug metabolizing enzymes on raltegravir is unknown and therefore not recommended.

Need a Curbside Consult? Positive evidence of raltegtavir fetal risk. Share Email Print Feedback Close. The use of other active agents with raltegravir is associated with a greater likelihood of treatment response. Renal impairment No dosage adjustment required for any degree of renal impairment Dialysis: Most commonly, these are “preferred” on formulary brand drugs.

Print with Office Info. View explanations for tiers and restrictions. Controlled studies in pregnant women show no evidence of fetal risk. This restriction typically limits the quantity of the drug that will be covered.

May be chewed or swallowed whole.

Raltegravir (MK, Isentress) –

Non-Medicare Plans Medicare Plans. There is a pregnancy exposure registry that monitors pregnancy outcomes in women; healthcare providers pacmage encouraged to register patients by calling the Antiretroviral Pregnancy Registry APR at 1- Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.

This drug is available at a higher level co-pay. Severe, potentially life-threatening and fatal skin reactions reported; skin reactions include cases of Stevens-Johnson syndrome, hypersensitivity reaction and toxic epidermal necrolysis; immediately discontinue treatment if severe hypersensitivity, severe rash, or rash with systemic symptoms or liver aminotransferase elevations develops and monitor clinical status, including liver aminotransferases closely.

If you log out, you will be required to enter your username and password the next time you visit. QL Quantity Limits Drugs that have quantity limits associated with each prescription.

Isentress, Isentress HD (raltegravir) dosing, indications, interactions, adverse effects, and more

This restriction typically requires that certain criteria be met prior to approval for the prescription. What would you like to print? Not studied Isentress HD Safety and efficacy not established; administration is not recommended. Significant – Monitor Closely. Contact the applicable plan provider for the most current information. OR Other Restrictions Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.

Sign Up It’s Free! Available data raltegravi APR show no difference in rate of overall birth defects for raltegravir compared to background rate for major birth defects of 2. Individual plans may vary and formulary information changes. Lactation The Centers for Disease Control and Prevention recommend that HIV-1 infected mothers in Rzltegravir States not breastfeed infants to avoid risking postnatal transmission of HIV-1 infection No data are available on presence of raltegravir in human milk, effects on breastfed infant, or on milk production; when administered to lactating rats, raltegravir was present in milk Owing to the potential for HIV transmission in HIV-negative infantsdeveloping viral resistance in HIV- positive infantsand adverse reactions in a breastfed infant, instruct mothers not to breastfeed if they are receiving therapy.